-
NMPA holds training on internal review of vaccine regulatory quality management system
2023-09-28
The National Medical Products Administration (NMPA) held a training on the internal review of vaccine regulatory quality management system in Beijing from Sept 18 to 19 to cultivate more internal review professionals.
-
Monkeypox classified as Class B infectious disease
2023-09-21
China has decided to manage monkeypox as a Class B infectious disease starting from Wednesday as the country reported about 500 cases last month, including its first infections detected in women, according to health authorities.
-
China releases second catalog of rare diseases
2023-09-21
Chinese health authorities have recently compiled the country's second catalog of rare diseases, the National Health Commission announced Wednesday.
-
NMPA Announcement on Adopting ICH Guidelines S12
2023-09-05
To align the technical standards for drug registration with international standards, the NMPA has decided upon deliberation to adopt the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines S12: Nonclinical Biodistribution Considerations for Gene Therapy Products(hereinafter referred to as S12).
-
NMPA Announcement on Adopting ICH Guidelines Q12
2023-08-25
To align the technical standards for drug registration with international standards, the NMPA has decided to adopt the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management.
-
Sunvozertinib Tablets Approved for Marketing by China NMPA
2023-08-23
Recently, the Category 1 innovative drug Sunvozertinib Tablets (Chinese trade name: 舒沃哲) of Dizal (Jiangsu) Pharmaceutical Co., Ltd is approved by China NMPA.
